Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012
Feb 13, 2018 Interim data further support potential of ME-344 to reverse resistance to antiangiogenic therapy
|
Feb 8, 2018 Pipeline advancement continues, including clearance of voruciclib IND by FDA and pracinostat Orphan Drug Designation by EMA
|
Dec 21, 2017 New Preclinical Studies Demonstrate Repression of MCL-1 and Sensitization to BCL-2 Inhibition in Diffuse Large B-Cell Lymphoma
|
Nov 22, 2017 Live Webcast from San Diego on November 30th
|
Nov 8, 2017 Quarter highlighted by dosing of first patient in pivotal Phase 3 study of pracinostat and exclusive license agreement for voruciclib
|
Live Webcast from New York on November 15th
|
Sep 19, 2017 Live Webcast from New York on September 26th
|
Sep 5, 2017 Clinical-Stage Asset in Validated Class of Drugs with Demonstrated Value
|
Company Begins New Fiscal Year with $53.6 Million in Cash
|
Live Webcasts from Boston on September 7th and New York on September 8th
|
